Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 4.16 EUR -0.95% Market Closed
Market Cap: 72.5m EUR
Have any thoughts about
Vita 34 AG?
Write Note

Vita 34 AG
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vita 34 AG
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Vita 34 AG
XETRA:V3V
Minority Interest
-€1m
CAGR 3-Years
-307%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Minority Interest
€1.3B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
12%
Fresenius SE & Co KGaA
XETRA:FRE
Minority Interest
€576m
CAGR 3-Years
-61%
CAGR 5-Years
-44%
CAGR 10-Years
-21%
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Minority Interest
HK$30.7m
CAGR 3-Years
-5%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Minority Interest
-€2.2m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Minority Interest
€1.3B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
12%
No Stocks Found

Vita 34 AG
Glance View

Market Cap
72.5m EUR
Industry
Health Care

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.

V3V Intrinsic Value
3.6 EUR
Overvaluation 13%
Intrinsic Value
Price

See Also

What is Vita 34 AG's Minority Interest?
Minority Interest
-1m EUR

Based on the financial report for Jun 30, 2024, Vita 34 AG's Minority Interest amounts to -1m EUR.

What is Vita 34 AG's Minority Interest growth rate?
Minority Interest CAGR 3Y
-307%

Over the last year, the Minority Interest growth was 8%. The average annual Minority Interest growth rates for Vita 34 AG have been -307% over the past three years .

Back to Top